ArticleBMJ oncology2026

Cost-effectiveness of neoadjuvant and adjuvant novel cancer therapies in stage II-III non-small cell lung cancer in Sri Lanka.

Nuradh Joseph et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.